NIDA-41020 is a CB1 cannabinoid receptor antagonist. NIDA-41020 is structurally similar to Rimonabant, which is currently in clinical development. NIDA-41020 is less lipophilic, and is developed at NIDA as a potential radioligand for CB1 receptors, Ki = 4.1 nM.
